|
ES2652304T3
(es)
|
2009-11-05 |
2018-02-01 |
Glaxosmithkline Llc |
Compuesto de benzodiacepina novedoso
|
|
US9102677B2
(en)
|
2009-11-05 |
2015-08-11 |
Glaxosmithkline Llc |
Benzodiazepine bromodomain inhibitor
|
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
|
EP2902030B1
(en)
|
2010-05-14 |
2016-09-14 |
Dana-Farber Cancer Institute, Inc. |
Thienotriazolodiazepine compounds for treating neoplasia
|
|
WO2011143660A2
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia
|
|
JP5844358B2
(ja)
|
2010-06-22 |
2016-01-13 |
グラクソスミスクライン エルエルシー |
ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201106743D0
(en)
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012151512A2
(en)
|
2011-05-04 |
2012-11-08 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
|
JP2016510039A
(ja)
*
|
2013-02-28 |
2016-04-04 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法
|
|
ES2704048T3
(es)
*
|
2013-03-14 |
2019-03-14 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
MX366703B
(es)
|
2013-03-15 |
2019-07-22 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de la proteína bet.
|
|
CA2901083A1
(en)
|
2013-04-26 |
2014-10-30 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
WO2015004534A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
CN105407888B
(zh)
|
2013-06-21 |
2019-05-21 |
齐尼思表观遗传学有限公司 |
新双环溴结构域抑制剂
|
|
WO2015006193A1
(en)
|
2013-07-08 |
2015-01-15 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
CA2918910A1
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9994581B2
(en)
|
2013-12-10 |
2018-06-12 |
Abbvie Inc. |
Bromodomain inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
KR20160115953A
(ko)
|
2014-01-31 |
2016-10-06 |
다나-파버 캔서 인스티튜트 인크. |
디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
|
|
JP2017504650A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
JP2017504651A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体の使用
|
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
|
SI3674302T1
(sl)
|
2014-04-23 |
2023-07-31 |
Incyte Holdings Corporation |
1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
|
|
PT3157928T
(pt)
|
2014-06-20 |
2019-05-30 |
Constellation Pharmaceuticals Inc |
Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida
|
|
JP2017526741A
(ja)
|
2014-08-08 |
2017-09-14 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
CN106793775B
(zh)
|
2014-08-08 |
2020-06-02 |
达纳-法伯癌症研究所股份有限公司 |
二氢碟啶酮衍生物及其用途
|
|
ES2705623T3
(es)
|
2014-09-12 |
2019-03-26 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de tetrahidroquinolina como inhibidores del bromodominio
|
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
|
CA2966298A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
EP3307725A1
(en)
|
2015-06-11 |
2018-04-18 |
Basilea Pharmaceutica International AG |
Efflux-pump inhibitors and therapeutic uses thereof
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
MX2017016337A
(es)
|
2015-06-26 |
2018-11-22 |
Tensha Therapeutics Inc |
Tratamiento de carcinoma de linea media nut.
|
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
HK1256419A1
(zh)
|
2015-09-11 |
2019-09-20 |
达纳-法伯癌症研究所股份有限公司 |
乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
|
|
US20170121347A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
SG10201913450PA
(en)
|
2015-11-25 |
2020-03-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CR20190027A
(es)
|
2016-06-20 |
2019-05-16 |
Incyte Corp |
Formas sólidas cristalinas de un inhibidor de bet
|
|
WO2018111805A1
(en)
*
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN114751836B
(zh)
*
|
2021-02-23 |
2024-05-31 |
四川青木制药有限公司 |
3-(4-甲基-1h-咪唑-1-基)-5-(三氟甲基)苯胺合成方法及其中间体
|
|
CA3255932A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution As |
ACTIVE COMPOUNDS AGAINST BROMODOMAINS
|